Showing posts with label FDA. Show all posts
Showing posts with label FDA. Show all posts

Thursday, August 6, 2009

FDA Commissioner: Six new compliance initiatives

FDA Commissioner Hamburg today:

Compliant industry should support these intitatives that will prevent them from being undercut by firms taking illegal shortcuts:

  • 15 days for FDA to issue Warning Letters. Warning letters will no longer be held waiting for firms to respond.

  • No GC reviews unless the case presents a novel legal issue. The Bush adminsitration policy of having letters reviewed by anti-consumer activitists planted in the Agency offices is cancelled.

  • State coordination where state law allows rapid response to seize products and correct issues.

  • A Warning Letter or recall will trigger enforcement follow up. Cases will no longer be allowed to languish or remain open with incertain resolution. Firms will get a knock on the door and an inspection.

  • No multiple warning letters. The second Warning Letter to a firm will trigger increased scrutiny and follow up actions.

  • After Warning Letter is satisfactorily resolved, firms may be eligible for a "close out letter" to document the matetrs have been resolved, e.g., after an FDA inspection.

Also she mentioned FDA has asked for additional power to mandatory food recalls.

The full text of the speech will be available immediately following the event here.

A video recording of the speech will be available after 4:00 this afternoon here.

Tuesday, August 4, 2009

FDA Food Safety Changes Round up

The FDA food safety law is written by Big Commercial Farms to keep FDA out of dirty Food, Inc.

Find out what food safety requirements didn't pass here and here, here thanks to the commercial farms that contaminate the animals we eat.
Findlaw on Food Safety: In the wake of recent food recalls, foodborne illnesses, and reports of unhygienic food processing conditions noted in some factories, the U.S. House of Representatives passed the Food Safety Enhancement Act this week in a vote of 283 to 142, significantly increasing resources for food inspection and quality control.

Although this article says FDA had no power over food imports, the law at Section 801 gives FDA MORE authority, allowing the agency to refuse to admit food that "appears" in violation, without having to prove that it is adulterated or filthy.

Here is a summary of the law.

Tuesday, July 28, 2009

Gallup: 38% say FDA is doing a good job, lower than IRS

It's true the IRS received the highest ratings since 1956, at 40%. However, confidence in FDA is even lower, at 38%.

"The Environmental Protection Agency, Internal Revenue Service, and Food and Drug Administration fall a notch lower in the rankings, as close to 40% of Americans give each of them credit for doing an excellent or good job. The relatively low ranking of the FDA is of particular note with regard to the scrutiny the agency has been under, given recent attention to U.S. food safety."

Monday, July 27, 2009

Thursday, March 26, 2009

Peanut Butter kills if companies don't qualify their vendors

More information about companies who audited Peanut Corporation of America and looked the other way because cost was more important than their customer's lives.


Nestlé's Inspectors Saw Rat Droppings, Rejected Peanuts

Nestlé USA, considering whether to buy ingredients from Peanut Corporation of America, twice sent its own inspectors to check out the company. Both times, they rejected the company after finding sanitary problems at its facilities in Georgia and Texas, noting rat droppings, live beetles, dead insects and the potential for microbial contamination.

What if Nestle Had Told the FDA?

FDA now accepts whistleblowers through its homepage

Monday, March 2, 2009

Industry: "Regulatory Incentives languish" for safety and efficacy

The gold standard in the regulated product industry, The Gold Sheet (Vol 43, No 1) has some advice for Regulatory and Quality staff. (RAQA are those staffers who told Peanut Corp of America that it would be illegal and dangerous to sell deadly contaminated peanut butter. ) Last month's Gold Sheet says death and jail is not enough to stop criminal profiteers - RAQA now has to show how complying with the law saves money. Why? because "regulatory incentives languish."


That means for the last 8 years, FDA has not been allowed to do its job. And regulated companies know it.

"FDA officials encourage industry to concentrate on the business benefits of [Quality by Design or] QbD. [Controlling manufacturing or] CMC pilot [program]s raised questions about cost effectiveness."

Wednesday, February 11, 2009

Peanut Butter and Salmonella, explained

When a product tests out of its specification, the product must be quarantined. That is why specifications exist.

The peanut butter made by the Peanut Butter Corporation of America tested positive for salmonella. It should have been quarantined.
What the manufacturer cannot do, is simply retest to see if another result will be produced. This has been prohibited by law for at least the past 15 years. But that's exactly what PCA did.
How many manufacturers simply retest? Under the current system there is no way to know. FDA, and the public health, depend on employees of the manufacturers themselves to stand up to marketing, sales, and even Presidents and CEOs, to prevent the shipment of contaminated foods, drugs, and devices. Some employees report to corrupt companies in corrupt countries far away. In this US facility, emails from PCA employees disclose a battered staff trying hard to get their company heads to follow the law. These employees are just a paycheck away from not working. This is a one of several gaping holes in the safety net.

FDA has no authority to recall many products without company approval.

FDA needs investigators now.

Wednesday, January 28, 2009

Is FDA finally free from politically driven decisions?

Just days after the inauguration, exciting projects that had been frozen for political reasons - even after researchers answered all safety and efficacy questions - are now underway.

One project has the promising goal "to achieve restoration of spinal cord function by the injection of hESC-derived oligodendrocyte progenitor cells directly into the lesion site of the patient's injured spinal cord."

Freezing this research that would help spine injured patients and their families was not the only significant politically motivated FDA action during the previous administration. For example, Plan B was delayed only to become the first and only over-the-counter product for preventing unwanted pregnancy that had a different standard for sexually active patients based on their age alone.

Susan Wood, the head of the Office of Women's Health protested, and payback was that women's health was de-funded. Wood then resigned.

Then-Commissiner Crawford admitted he had delayed approval of Plan B, a product that proved it prevented high-risk pregnancies and saved patient lives. The criminal investigation of the Commissioner was revealed in 2006, shortly after he had resigned in September 2005. He had been confirmed by the Senate for less than three months as the permanent FDA commissioner, a position which he had held on an “acting” basis for a couple of years. It turned out he invested in companies with applications pending at FDA.

Tuesday, January 13, 2009

More FDA Changes: New Acting Commissioner, more allegations

WSJ: The new Acting Commissioner is Food and Drug Administration Chief Scientist Frank Torti.

Dr. Frank Torti, the FDA's science chief, is set to become its acting commissioner. President-elect Barack Obama and his transition team could announce a permanent
appointee to lead the FDA in the next three weeks, sources said. Wall Street Journal, (subscription required) (01/12)

William Gimson III, chief operating officer at the CDC, will serve as acting director after Dr. Julie Gerberding leaves the agency Jan. 20.
Torti will have his hands full right away - nine device scientists report being pressured to approve unsafe and ineffective products. In the letter, the scientists described an agency where President Bush's FDA managers "ordered, intimidated and coerced scientists to manipulate their research results in violation of federal law."

Friday, January 9, 2009

Sydney Wolf joins FDA

WSJ: Now the outsider [from Ralph Nader's Health Research Group] is going inside, mirroring a larger shift in the Washington pendulum toward tougher company regulation. To the consternation of the drug industry, Dr. Wolfe has been appointed to a four-year term on the FDA's Drug Safety and Risk Management Committee, which plays a key role in telling the agency which drugs are safe.

What's more, he has the ear of several health leaders and members of Congress expected to influence FDA policy in the Obama administration. Joshua Sharfstein, a former aide to liberal Rep. Henry Waxman, who is leading the Obama transition team assessing the FDA, worked for Dr. Wolfe years ago.

Thursday, March 20, 2008

Qualify your vendors: Heparin from China

FDA has user fees to review drug applications but this administration has forced budget cuts that have decimated it's ability to inspect manufacturing plants not just for drugs, but for devices, biological products, food, and veterinary medicine. FDA inspectors wait until the agency can bundle up foreign establishment inspections, and then only give FDA inspectors a few days in each site to spot-check records.

That means facilities must police themselves.

Instead, the Heparin contamination is just another example of how US companies have downsized their operations and their Quality units to please shareholders, and now these companies obtain many of their components from the third world where corruption is common, contamination from dirty water and unhygienic practices is unavoidable, and subcontractors think nothing of exchanging expensive ingredients and equipment with unacceptable replacements. US companies don't know their vendors, they don't adequately audit them, and they don't know where their vendors get their supplies, either. This despite the fact that the idea of qualifying vendors has been around since 1951.

WSJ writes without much new insight that "The recent problems with heparin from China highlight the difficulty of monitoring the often diffuse and poorly regulated supply chains there -- for both Chinese drug makers and the multinational pharmaceutical companies that buy from them."

Like many regulated companies, this one falls into the trap of bragging that it built a new "GMP facility;" then fails to make sure the people and products brought into its new walls are free from contamination.

WaPo quotes William Hubbard, a former FDA official, who says it is not surprising that tainted drugs supplied though agency-approved channels are showing up from abroad. "The history of some of these developing countries in terms of substituting or counterfeiting concerns is a long and well-documented one," he said. "And at this point, the FDA doesn't have the resources or system in place to make sure some of these bad drugs don't get through to the public."

In the meantime, FDA budget is still a fraction of NIH's, and increases for FY09 are barely enough to cover cost of living adjustments, and certainly won'y allow improvements in inspections. Even industry wants to give FDA more money.

Tuesday, December 4, 2007

American Lives are at risk

Congress has enacted 125 statutes giving the FDA new or expanded responsibilities since 1988, without any new funding to cover the extra work. HuffPo has the story.

An FDA advisory board concluded the situation is dire. "FDA's inability to keep up with scientific advances means that American lives are at risk," the report concluded. A report by the Institute of Medicine in 2006 reached the same conclusion, but the Republican-controlled Congress did nothing to improve the safety of the infant formula, pet food, toothpaste, spinich, prescription drugs and implants relied upon by millions of Americans.

In the wake of the scathing report detailing the dangerously poor state of the Food and Drug Administration, President Bush is threatening to veto much-needed funds for the agency.

Rep. Rosa DeLauro, D-CT, who leads the House panel responsible for FDA funding, called on President Bush to lift his objections to the agriculture appropriations bill, in which there is a drastic increase in money for the FDA. Without the infusion of cash, DeLauro said, U.S. consumers would be at great risk regarding food and drug safety.

The FDA Alliance and the Coalition for a Stronger FDA have issued a press release alerting us that the nation's food supply is at risk, as are the regulatory systems that oversee the nation's drug and device supplies, according to a subcommittee of the FDA's Science Board in a report it presented on December 3. They conclude that this imbalance is imposing a significant risk to the integrity of the food, drug, cosmetic and device regulatory system, and hence the safety of the public.

The result of a year-long review by a distinguished panel of experts, the 300-page report concludes that the state of FDA's scientific and regulatory programs could not be separated from the lack of resources available to support the agency's scientific base, hire and train a broadly-capable scientific workforce, and build a sophisticated and modern information technology infrastructure. You can find the report here.

FDA's need for recall authority here

Tuesday, August 28, 2007

FDA in danger of being FEMA-ized

Burton J. Howard, chief of the Bureau of Chemistry's (now FDA) microchemical laboratory, is shown in the right foreground in this photo from the 1920s. Howard developed a quantitative method to detect mold in ketchup that proved to be indispensable in establishing food adulteration in court.

Grover Norquist was realizing his dream to "drown government in a bathtub" when he lobbied Congress to shrink agencies like the Federal Emergency Management Administration. FEMA had been riding high after being turned around by Republican appointee Frank Young, whose career hit its stride at FEMA. Other countries sent experts to the US to copy FEMA's efforts.

Then FEMA was underfunded, outsourced, ignored and effectively dismantled in time for Hurricane Katrina in 2005. Now another public service agency, the Food and Drug Administration (FDA), is in danger of the same fate: the Administration plans to close labs and outsource jobs.

Despite a glaring need for more resources, made apparent by dangers from contaminated imports like contaminated drugs fromChina, toothpaste made with anti-freeze, and pet food contaminated with melamine, the local county's school system in Montgomery County has more staff and a bigger budget than all the nation's food, drug, blood and device inspectors. Compare the NIH budget for 2007 of $28.6 Billion, with FDA's budget: FDA gets 1/20th of that, at under $1.5 billion.

When Congress refused to fully fund the Agency for decades, first drug manufacturers then device makers banded together to agree to pay fees to hire reviewers. Still, the funding law prohibits using those fees for compliance and inspection actions, and AIDS and bioterrorism initiatives continue to funnel resources away from the Agency's core functions.

Bush and his team have already forgotten the still-raw lessons from Katrina and the administration is making stealth progress on an initiative to reduce staff, close laboratories, and contract out the Agency's work.

FDA plans were - and still are - to close seven of its 13 laboratories. The politicians say fewer labs would be more efficient. However, Energy and Commerce investigators disagree with FDA's justification for the reorganization. The Tan Sheet, which covers OTC drugs, said it best:

"Despite repeated requests from the committee, FDA has failed to provide any analysis justifying this radical reorganization," Senior Investigator David Nelson, Investigative Counsel Kevin Barstow and Investigator Richard Wilfong say in written testimony.

"Since FDA has not provided an analysis demonstrating any cost-savings associated with the lab closures, their rationale implies that synergies exist in mega-labs; however, no documents have been produced by FDA to support that suggestion," the investigators say.

Additionally, they cite a Government Accountability Office report determining midsize labs are more efficient than mega-labs.

"FDA has failed to provide us with any independent cost-benefit analysis for their proposal," they say. "On the surface the proposed closings appear to be counterproductive and may needlessly increase taxpayers' costs."

When FDA refused to cooperate with Congressional questions, Congress threatened to prohibit use of any funds to implement the transfer. Margaret Glavin, associate commissioner for regulatory affairs at FDA, wrote in a letter to Office of Regulatory Affairs employees that she is "canceling plans for the rollout of all changes to our organizational structure." According to WaPo, "Two House members from Michigan, Reps. John D. Dingell (D) and Bart Stupak (D), hailed the e-mail as an indication of FDA's decision to "abandon" its reorganization. But agency spokeswoman Julie Zawisza denied that the agency had canceled its plans." WaPo: "FDA spokeswoman Julie Zawisza said in an e-mail that Friday's announcement left open the possibility of future changes."

In addition to the closures, FDA has added an initiative to outsource the jobs in the field offices. These offices are often the place where industry comes face-to-face with Agencies in the FDA districts and where laboratory tests to confirm preliminary results are performed. According to Forbes:

The government's chief health regulatory agency is reviewing more than 300 positions in more than 20 cities to determine whether they could be performed cheaper and better by the private sector. A decision is expected next month, according to FDA documents.

An initial list of positions under review included lab technicians and field office workers who work at FDA facilities where food and medical products are inspected for safety.

The vast majority of FDA experts, in a survey that includes experts inside and outside the FDA, agree the FDA does not have the strong leadership it needs. FDA needs a leader who will demand full funding for FDA.

GovExec 08/20/2007
Federal Times 08/20/2007
DailyKos Diary

Friday, August 17, 2007

Margaritas, Drugs, Devices and Biologics

RAPS’ Washington/Baltimore Metropolitan Area Chapter is pleased to announce a Summer Happy Hour Network Event.

This event provides an opportunity to informally meet other RAPS members in the area in a casual atmosphere. Chapter leaders have asked several local industry representatives and others in the area of drug and device development/regulations to join us.

This is an unofficial event, but we would like to know in advance if you plan to attend. This will help us know how many folks we are looking for upon arrival.

When: 22 August 2007 (Wednesday)
Where: Guapos Cantina at the Washingtonian, Gaithersburg, MD
Time: 5:00–8:00 pm

R.S.V.P to chapters@raps.org.

Please note that RAPS is assisting us in getting out the message, however, this is not a RAPS Headquarters-sponsored event. There will be a cash bar for this event. The cost for food will be the responsibility of each attendee.

Feel free to comment, especially if you can attend!


Regulatory Affairs Professionals Society
11300 Rockville Pike, Suite 1000,
Rockville, MD 20852
Main Phone: 301.770.2920; Fax: 301.770.2924
RAPS Solutions Center: 301.770.2920, ext. 200
Email: raps@raps.org; website: http://www.raps.org/
RAPS® —Making better healthcare products possible

Friday, June 1, 2007

Bill Hubbard's FDA Letter-Wrongly Blaming The FDA

If you want to know how contaminated pet food threatened livestock and the food supply in the US, read this. (The links are mine.)

The current FDA, suffering from a decade without a strong leader and another emerging scandal, needs tools to keep consumer safe, and it's not getting them. The administration's current plans, to close laboratories and facilities in N.J. and Puerto Rico, home to the country's major drug manufacturing operations, could cripple its enforcement ability.

This photograph is an FDA staffer with a typical drug application for the time, about 1965.

By William Hubbard, Monday, WaPo, May 8, 2006; Page A19

Last month the Government Accountability Office released another report criticizing the Food and Drug Administration's efforts to ensure the safety of prescription drugs. It seems to have become great sport for public officials to revel in FDA shortcomings. Time after time in recent years, FDA scientists have warned of threats to the safety of the nation's food and drugs, sought new resources and tools to deal with those threats, and been duly dismissed. Yet when their predictions have come true, decision makers of all political stripes rush to bemoan the agency's failures.

* * * *
FDA scientists have done as they promised -- new drugs have been sped to market, and the FDA leads the world in approval times. But the companies often fail to do the needed safety studies, and Congress has taken no steps to allow the agency to compel them. FDA scientists also recognized that rapid drug approvals can miss important safety indicators and requested funding to create state-of-the-art systems to monitor drug safety. The new dollars that the White House proposed and Congress provided for this come to a nice round number: zero.

* * * *
For most of the FDA's 100-year history, presidents and congresses have recognized its importance to public health by giving it the resources and authority to respond to the rapid evolution in risks from the thousands of products it regulates. But for some years now, the agency's budget has remained essentially flat while major new responsibilities have been piled on. The results of this weakening of the agency are easy to document: Food inspections have dropped from a robust 50,000 in 1972 to about 5,000 today, meaning that U.S. food processors are inspected on average about every 10 years. The chance of a food product from overseas being inspected is infinitesimal. Most raw materials for our drugs come from foreign producers that are rarely inspected. The rate of quality-control failures found in manufacturing facilities by FDA inspectors has soared. Think your pacemaker, heart valve, microwave oven or morning vitamin was inspected? Dream on.

How much does Congress appropriate for the agency that has responsibility for the safety of the whole country's supply of food, drugs, vaccines, medical devices, cosmetics, animal foods and drugs, dietary supplements, and more? The same amount as Fairfax County, Va., provides for its schools.

The future could get worse...

[There are] developments and innovations [that] hold the promise of transforming the terrain of modern medicine and food production. FDA officials have been trying mightily to get the attention of decision makers who can give them the ability to adequately oversee these things. And, in a post-Sept. 11 world, there are new challenges to the food and drug supply that I cannot even hint at publicly.

Sens. Orrin Hatch and Edward Kennedy and a few other political leaders have expressed concern about the effects of starving what has been the world's foremost consumer protection agency. But most legislators are content to await the emergence of problems rather than head them off.

Maybe the FDA's scientists can keep their finger in the dike. Maybe we'll be lucky and avoid a major crisis. But maybe the great Dodger baseball executive Branch Rickey got it right: When asked how much luck played into his teams' success, he scoffed that luck was a residue of design. If we keep failing the FDA, and the FDA in turn fails, it's inevitable that our luck will run out.

The writer retired last year after more than 25 years at the Food and Drug Administration, the last 14 as associate commissioner.

Monday, March 12, 2007

FDA regulation - around the horn

I've been asked before to blog on health care and the Pharma industry, and accused of being unwilling to subject my own industry to scrutiny. The truth is, it's difficult for me to write about something that I'm entrenched in, because I don't know when to stop. Also, there are other, better bloggers than I who've attacked this subject, so I'm using this spot to highlight them.

I have written a little on this, and here is my Amazon "How to" on this subject. My writings for RAPS are here (membership required)

Piper Report. Kip Piper has a blog and an Amazon "How To" also.

Other good blogs include these:

Drug Channels
Eye on FDA
Gooz News
Orange Book blog
Pharma Marketing Blog

Other great links to the industry:

ASQ, American Society for Quality. Look for special interest groups in biomedical, pharmaceutical, and foods/drugs/cosmetics.

Barnett International. Lots of $$ courses.

BIO, BioTech Industry Assn.

BioPortfolio Biotechnology and Pharmaceutical Press Release News and Headlines.

BioSpace. News, calendar and comments by region and industry and company.

Connect.org Calendar. San Diego, CA.

DIA, Drug Information Association. Best job board in the industry.

FDA website.
FDA Advisory Committee Meetings. Watch Agency and industry science work together.
Center for Devices and Radiological Health: FDA CDRH ww.fda.gov/cdrh/.

Center for Drug Evaluation and Research: FDA CDER www.fda.gov/cder.
FDA News Digest, FDA News Digest is a free newsletter that presents the latest FDA information. Sign up at the above URL, go to browse, and search for FDA- NewsDigest -L.

FDANews: FDA News: FDA News FDA News has free daily bulletins; annual fees apply to access some links. If there's a story that interests you, you can often find it for free; use the keywords to search for the story on FDA's website or in reputable papers.
FDAAA, FDA Alumni Association. For former FDA'ers, and current ones as associate members.

FDLI, Food and Drug Law Institute. An educational network of FDA lawyers.
FDLI’s SmartBrief. Free. Other related newsletters at www.smartbrief.com/signup/
Federal Register. The Federal "daily newspaper." Find out what your government is doing. Sign up to freely receive the daily Federal Register Table of Contents via e-mail.

Findlaw. For lawyers and other people who want to keep track of what this branch of the government is up to, have court summaries and full text links emailed to you.

Freedom of Information: FOI services summarizes documents released by FDA (some of which are available free on the FDA site). It also publishes a "Free Document of the Week."

GBTC Greater Baltimore Technology Council: The GBTC works to grow the region's tech community.

Hogan and Hartson (law firm) FDA related events.

IIRUSA, International Institute for Research - USA.

IQPC, International Quality & Productivity Center.

JHU Government related symposia. This includes a list of some of the other think tanks and other organizations that have public meetings regularly in the DC area for discussions on politics and government.

Maryland Hi Tech Council. The Technology Council of Maryland (TCM), founded in 1986, is an association of technology firms, federal laboratories, education institutions and business support firms that collectively form Maryland's technology community. TCM represents thousands of knowledge-based employees in the state and region.

MdBio, Maryland BioTech Industry Org. A private, non-profit corporation that offers a variety of programs to advance the commercial development of bioscience in Md.

New York Times on FDA. Read the latest stories in the free paper with the best FDA coverage. Registration required.

PDA, Parenteral Drug Association. An educational association, very active on manufacturing issues.
PDA local chapter in DC Metro. This chapter has good meetings but unfortunately
a website that is not updated frequently. Get on their email list if you don't
see anything coming up.

PDA local chapters nationwide. These PDA meetings are short, cheap, and nationwide.
Pharmacy Times On line "quick course" with regulatory emphasis.

PQRI, Product Quality Research Institute.

RAPS, Regulatory Affairs Professional Association.

San Jose (CA) BioCenter.

Thompson Publishing Group News. Free newsletters, but links of additional news are for subscribers. If there are stories that interest you, use the keywords to search for the story on FDA's website or in reputable papers.

WA Bio, Washington (State) Bio.

Monday, January 22, 2007

FDA Round Up around the Beltway

FDA is reeling and reorganizing.